Product Licensing

NorDiag ASA and Transgenomic enter exclusive European license and supply agreement for Wave System

Published in Cancer Weekly, March 21st, 2006

NorDiag ASA and Transgenomic Inc. announced that they have entered into an exclusive license and supply agreement which will unite the two companies' technologies in the fight against colorectal and pancreatic cancer.

Transgenomic has granted NorDiag exclusive European commercial rights to use its proprietary Wave System and associated consumables to perform molecular diagnostic testing for the detection of colorectal and pancreatic cancer from stool samples. NorDiag, in return, will pay a licensing fee and has committed to certain minimum annual purchases.

NorDiag successfully employs the Wave System in its Genefec test, which can detect mutations...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2006-03-21)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry